Off-label drug use in Europe is very small because it is almost never reimbursed. I expect no significant off-label use of Atryn based on approval for the HD indication. Regards, Dew
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”